Importer of Controlled Substances; Notice of Application, 36482-36483 [E7-12954]

Download as PDF 36482 Federal Register / Vol. 72, No. 127 / Tuesday, July 3, 2007 / Notices CFR 1301.34(b), (c), (d), (e) and (f) are satisfied. DEPARTMENT OF JUSTICE Dated: June 26, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–12941 Filed 7–2–07; 8:45 am] Drug Enforcement Administration BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Importer of Controlled Substances; Notice of Application Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this is notice that on February 2, 2007, Lipomed, Inc., One Broadway, Cambridge, Massachusetts 02142, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedules II: Drug Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 13, 2007, Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066–1742, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule II: Drug Schedule Cocaine (9041) ............................. Ecgonine (9180) ........................... II II jlentini on PROD1PC65 with NOTICES The company plans on producing cocaine for sale to its customers, who are final dosage manufacturers. The ecgonine is formed during the manufacturing process for cocaine. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administrator, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537; or any being sent via express mail should be sent to Drug Enforcement Administration, Federal Register Representative (ODL); 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 4, 2007. Dated: June 26, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–12947 Filed 7–2–07; 8:45 am] BILLING CODE 4410–09–P VerDate Aug<31>2005 17:57 Jul 02, 2007 Jkt 211001 Drug Schedule Cathinone (1235) .......................... Methcathinone (1237) .................. N-Ethylamphetamine (1475) ........ Methaqualone (2565) ................... Gamma Hydroxybutyric Acid (2010). Lysergic acid diethylamide (7315) 2,5–Dimethoxy-4-(n)propylthiophenethylamine (7348). Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... Mescaline (7381) .......................... 3,4,5–Trimethoxyamphetamine (7390). 4–Bromo-2,5dimethoxyamphetamine (7391). 4–Bromo-2,5dimethoxyphenethylamine (7392). 4–Methyl-2,5dimethoxyamphetamine (7395). 2,5–Dimethoxyamphetamine (7396). 2,5–Dimethoxy-4ethylamphetamine (7399). 3,4–Methylenedioxyamphetamine (7400). 3,4–Methylenedioxy-Nethylamphetamine (7404). 3,4– Methylenedioxymethamphetamine (7405). 4–Methoxyamphetamine (7411) ... Dimethyltryptamine (7435) ........... Psilocybin (7437) .......................... Psilocyn (7438) ............................. Acetyldihydrocodeine (9051) ........ Dihydromorphine (9145) ............... Heroin (9200) ............................... Normorphine (9313) ..................... Pholcodine (9314) ........................ Tilidine (9750) ............................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Phencyclidine (7471) .................... Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Benzoylecgonine (9180) ............... PO 00000 Frm 00064 Fmt 4703 Sfmt 4703 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II II II II II II II II II II II Ethylmorphine (9190) ................... Hydrocodone (9193) ..................... Levorphanol (9220) ...................... Meperidine (9230) ........................ Methadone (9250) ........................ Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... Alfentanil (9737) ........................... Fentanyl (9801) ............................ Sufentanil (9740) .......................... Schedule II II II II II II II II II II II II The company plans to import analytical reference standards for distribution to its customers for research and analytical purposes. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedule I or II, which fall under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C 952 (a)(2)(B) may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537; or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than August 2, 2007. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745), all applicants for registration to import a basic class of any controlled substances in schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C 958(a); 21 U.S.C 823(a); and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied. E:\FR\FM\03JYN1.SGM 03JYN1 36483 Federal Register / Vol. 72, No. 127 / Tuesday, July 3, 2007 / Notices Dated: June 26, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–12954 Filed 7–2–07; 8:45 am] DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Manufacturer of Controlled Substances; Notice of Registration BILLING CODE 4410–09–P Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 8, 2007, Penick Corporation, 33 Industrial Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule II: By Notice dated March 19, 2007, and published in the Federal Register on March 27, 2007, (72 FR 14297), Roche Diagnostics Operations, Inc., Attn: Regulatory Compliance, 9115 Hague Road, Indianapolis, Indiana 46250, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 15, 2007, Lonza Riverside, 900 River Road, Conshohocken, Pennsylvania 19428, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule II: Drug Schedule Drug Schedule Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Diphenoxylate (9170) ................... Ecgonine (9180) ........................... Hydrocodone (9193) ..................... Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... II II II II II II II II II II II Drug Lysergic Acid Diethylamide (7315) Tetrahydrocannabinols (7370) ..... Alphamethadol (9605) .................. Phencyclidine (7471) .................... Ecgonine (9180) ........................... Methadone (9250) ........................ Morphine (9300) ........................... Schedule I I I II II II II The company plans to manufacture bulk products for finished dosage units and distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 4, 2007. The company plans to manufacture the listed controlled substances as bulk controlled substance intermediates for distribution to its customers for further manufacture or to manufacture pharmaceutical dosage forms. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 4, 2007. The company plans to manufacture small quantities of the listed controlled substances for use in diagnostic products. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Roche Diagnostics Operations, Inc., to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Roche Diagnostics Operations, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: June 26, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–12946 Filed 7–2–07; 8:45 am] Dated: June 26, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–12945 Filed 7–2–07; 8:45 am] Dated: June 26, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–12951 Filed 7–2–07; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P BILLING CODE 4410–09–P jlentini on PROD1PC65 with NOTICES Gamma hydroxybutyric acid (2010). Amphetamine (1100) .................... Methylphenidate (1724) ................ VerDate Aug<31>2005 17:57 Jul 02, 2007 I II II Jkt 211001 PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 E:\FR\FM\03JYN1.SGM 03JYN1

Agencies

[Federal Register Volume 72, Number 127 (Tuesday, July 3, 2007)]
[Notices]
[Pages 36482-36483]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-12954]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this 
is notice that on February 2, 2007, Lipomed, Inc., One Broadway, 
Cambridge, Massachusetts 02142, made application by renewal to the Drug 
Enforcement Administration (DEA) for registration as an importer of the 
basic classes of controlled substances listed in schedules II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235)...........................  I
Methcathinone (1237).......................  I
N-Ethylamphetamine (1475)..................  I
Methaqualone (2565)........................  I
Gamma Hydroxybutyric Acid (2010)...........  I
Lysergic acid diethylamide (7315)..........  I
2,5-Dimethoxy-4-(n)-                         I
 propylthiophenethylamine (7348).
Marihuana (7360)...........................  I
Tetrahydrocannabinols (7370)...............  I
Mescaline (7381)...........................  I
3,4,5-Trimethoxyamphetamine (7390).........  I
4-Bromo-2,5-dimethoxyamphetamine (7391)....  I
4-Bromo-2,5-dimethoxyphenethylamine (7392).  I
4-Methyl-2,5-dimethoxyamphetamine (7395)...  I
2,5-Dimethoxyamphetamine (7396)............  I
2,5-Dimethoxy-4-ethylamphetamine (7399)....  I
3,4-Methylenedioxyamphetamine (7400).......  I
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxymethamphetamine (7405)...  I
4-Methoxyamphetamine (7411)................  I
Dimethyltryptamine (7435)..................  I
Psilocybin (7437)..........................  I
Psilocyn (7438)............................  I
Acetyldihydrocodeine (9051)................  I
Dihydromorphine (9145).....................  I
Heroin (9200)..............................  I
Normorphine (9313).........................  I
Pholcodine (9314)..........................  I
Tilidine (9750)............................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Amobarbital (2125).........................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
Phencyclidine (7471).......................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Benzoylecgonine (9180).....................  II
Ethylmorphine (9190).......................  II
Hydrocodone (9193).........................  II
Levorphanol (9220).........................  II
Meperidine (9230)..........................  II
Methadone (9250)...........................  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Morphine (9300)............................  II
Thebaine (9333)............................  II
Oxymorphone (9652).........................  II
Alfentanil (9737)..........................  II
Fentanyl (9801)............................  II
Sufentanil (9740)..........................  II
------------------------------------------------------------------------

    The company plans to import analytical reference standards for 
distribution to its customers for research and analytical purposes.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic classes of controlled 
substances listed in schedule I or II, which fall under the authority 
of section 1002(a)(2)(B) of the Act (21 U.S.C 952 (a)(2)(B) may file 
comments or objections to the issuance of the proposed registration and 
may, at the same time, file a written request for a hearing on such 
application pursuant to 21 CFR 1301.43 and in such form as prescribed 
by 21 CFR 1316.47.
    Any such comments or objections being sent via regular mail should 
be addressed, in quintuplicate, to the Drug Enforcement Administration, 
Office of Diversion Control, Federal Register Representative (ODL), 
Washington, DC 20537; or any being sent via express mail should be sent 
to Drug Enforcement Administration, Office of Diversion Control, 
Federal Register Representative (ODL), 2401 Jefferson Davis Highway, 
Alexandria, Virginia 22301; and must be filed no later than August 2, 
2007.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e) and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, (40 FR 43745), all applicants for 
registration to import a basic class of any controlled substances in 
schedule I or II are and will continue to be required to demonstrate to 
the Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration, that the requirements for such registration 
pursuant to 21 U.S.C 958(a); 21 U.S.C 823(a); and 21 CFR 1301.34(b), 
(c), (d), (e) and (f) are satisfied.


[[Page 36483]]


    Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E7-12954 Filed 7-2-07; 8:45 am]
BILLING CODE 4410-09-P